GRI Bio Inc. (GRI)vsEli Lilly and Company (LLY)
GRI
GRI Bio Inc.
$2.18
-2.25%
HEALTHCARE · Cap: $3.41M
LLY
Eli Lilly and Company
$934.60
+9.80%
HEALTHCARE · Cap: $760.43B
Smart Verdict
WallStSmart Research — data-driven comparison
LLY leads profitability with a 31.7% profit margin vs 0.0%. LLY earns a higher WallStSmart Score of 78/100 (B+).
GRI
Avoid26
out of 100
Grade: F
LLY
Strong Buy78
out of 100
Grade: B+
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 101 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 44.9%
Revenue surging 42.6% year-over-year
Earnings expanding 51.4% YoY
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 31.5x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : GRI
The strongest argument for GRI centers on Price/Book, Debt/Equity.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.7% and operating margin at 44.9%. Revenue growth of 42.6% demonstrates continued momentum.
Bear Case : GRI
The primary concerns for GRI are Revenue Growth, EPS Growth, Market Cap.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.60 is elevated, increasing financial risk.
Key Dynamics to Monitor
GRI profiles as a value stock while LLY is a growth play — different risk/reward profiles.
LLY carries more volatility with a beta of 0.50 — expect wider price swings.
LLY is growing revenue faster at 42.6% — sustainability is the question.
LLY generates stronger free cash flow (678M), providing more financial flexibility.
Bottom Line
LLY scores higher overall (78/100 vs 26/100), backed by strong 31.7% margins and 42.6% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
GRI Bio Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
GRI Bio Inc. is a cutting-edge biotechnology company focused on revolutionizing patient care through its proprietary microbiome technology platform. With a strong emphasis on developing innovative therapies specifically targeting unmet medical needs in immunology and oncology, GRI Bio strives to tackle the underlying causes of diseases rather than just their symptoms. The company has established a robust pipeline of product candidates and strategic research partnerships, positioning it for notable growth and a leadership role in the burgeoning field of microbiome therapeutics. Committed to enhancing patient outcomes, GRI Bio is well-equipped to make significant contributions to the future of healthcare solutions.
Visit Website →Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?